287 related articles for article (PubMed ID: 38347839)
21. Artificial intelligence CT radiomics to predict early recurrence of intrahepatic cholangiocarcinoma: a multicenter study.
Song Y; Zhou G; Zhou Y; Xu Y; Zhang J; Zhang K; He P; Chen M; Liu Y; Sun J; Hu C; Li M; Liao M; Zhang Y; Liao W; Zhou Y
Hepatol Int; 2023 Aug; 17(4):1016-1027. PubMed ID: 36821045
[TBL] [Abstract][Full Text] [Related]
22. Dual-Specificity Phosphatase 11 Is a Prognostic Biomarker of Intrahepatic Cholangiocarcinoma.
Xu L; Wang P; Zhang W; Li W; Liu T; Che X
Front Oncol; 2021; 11():757498. PubMed ID: 34660327
[TBL] [Abstract][Full Text] [Related]
23. Artificial intelligence as an emerging technology in the current care of neurological disorders.
Patel UK; Anwar A; Saleem S; Malik P; Rasul B; Patel K; Yao R; Seshadri A; Yousufuddin M; Arumaithurai K
J Neurol; 2021 May; 268(5):1623-1642. PubMed ID: 31451912
[TBL] [Abstract][Full Text] [Related]
24. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas.
Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM
Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148
[TBL] [Abstract][Full Text] [Related]
25. Cholangiocarcinoma: anatomical location-dependent clinical, prognostic, and genetic disparities.
Hang H; Jeong S; Sha M; Kong D; Xi Z; Tong Y; Xia Q
Ann Transl Med; 2019 Dec; 7(23):744. PubMed ID: 32042760
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma.
Padthaisong S; Thanee M; Namwat N; Phetcharaburanin J; Klanrit P; Khuntikeo N; Titapun A; Sungkhamanon S; Saya H; Loilome W
J Transl Med; 2020 Feb; 18(1):64. PubMed ID: 32039729
[TBL] [Abstract][Full Text] [Related]
27. AI-based digital histopathology for perihilar cholangiocarcinoma: A step, not a jump.
Hoyer DP; Ting S; Rogacka N; Koitka S; Hosch R; Flaschel N; Haubold J; Malamutmann E; Stüben BO; Treckmann J; Nensa F; Baldini G
J Pathol Inform; 2024 Dec; 15():100345. PubMed ID: 38075015
[TBL] [Abstract][Full Text] [Related]
28. Cholangiocarcinoma.
Khan AS; Dageforde LA
Surg Clin North Am; 2019 Apr; 99(2):315-335. PubMed ID: 30846037
[TBL] [Abstract][Full Text] [Related]
29. Application of Artificial Intelligence in Dentistry.
Shan T; Tay FR; Gu L
J Dent Res; 2021 Mar; 100(3):232-244. PubMed ID: 33118431
[TBL] [Abstract][Full Text] [Related]
30. Cholangiocarcinoma in patients with primary sclerosing cholangitis.
Fung BM; Tabibian JH
Curr Opin Gastroenterol; 2020 Mar; 36(2):77-84. PubMed ID: 31850928
[TBL] [Abstract][Full Text] [Related]
31. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions.
Macias RIR; Cardinale V; Kendall TJ; Avila MA; Guido M; Coulouarn C; Braconi C; Frampton AE; Bridgewater J; Overi D; Pereira SP; Rengo M; Kather JN; Lamarca A; Pedica F; Forner A; Valle JW; Gaudio E; Alvaro D; Banales JM; Carpino G
Gut; 2022 Aug; 71(8):1669-1683. PubMed ID: 35580963
[TBL] [Abstract][Full Text] [Related]
32. Development and validation of a clinical prediction model for the risk of distal metastasis in intrahepatic cholangiocarcinoma: a real-world study.
Fang C; Xu C; Jia X; Li X; Yin C; Xing X; Li W; Wang Z
BMC Gastroenterol; 2024 Jan; 24(1):1. PubMed ID: 38166611
[TBL] [Abstract][Full Text] [Related]
33. Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma.
Zheng Y; Qin Y; Gong W; Li H; Li B; Wang Y; Chao B; Zhao S; Liu L; Yao S; Shi J; Shi X; Wang K; Xu S
J Gastrointest Oncol; 2021 Dec; 12(6):2631-2642. PubMed ID: 35070393
[TBL] [Abstract][Full Text] [Related]
34. Pathogenesis, diagnosis, and management of cholangiocarcinoma.
Ilyas SI; Gores GJ
Gastroenterology; 2013 Dec; 145(6):1215-29. PubMed ID: 24140396
[TBL] [Abstract][Full Text] [Related]
35. FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience.
Hrudka J; Prouzová Z; Mydlíková K; Jedličková K; Holešta M; Whitley A; Havlůj L
Pathol Oncol Res; 2021; 27():1609756. PubMed ID: 34257615
[TBL] [Abstract][Full Text] [Related]
36. Early postoperative decrease of skeletal muscle mass predicts recurrence and poor survival after surgical resection for perihilar cholangiocarcinoma.
Yasuta S; Sugimoto M; Kudo M; Kobayashi S; Takahashi S; Konishi M; Gotohda N
BMC Cancer; 2022 Dec; 22(1):1358. PubMed ID: 36578076
[TBL] [Abstract][Full Text] [Related]
37. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
38. Current Surgical Management of Peri-Hilar and Intra-Hepatic Cholangiocarcinoma.
Lauterio A; De Carlis R; Centonze L; Buscemi V; Incarbone N; Vella I; De Carlis L
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359560
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100354. PubMed ID: 33756174
[TBL] [Abstract][Full Text] [Related]
40. Predicting cholangiocarcinoma in primary sclerosing cholangitis: using artificial intelligence, clinical and laboratory data.
Hu C; Iyer RK; Juran BD; McCauley BM; Atkinson EJ; Eaton JE; Ali AH; Lazaridis KN
BMC Gastroenterol; 2023 Apr; 23(1):129. PubMed ID: 37076803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
